Glaxosmithkline Pharmaceuticals Reports Mixed Financial Results Amid Debt Management Concerns in February 2025
Glaxosmithkline Pharmaceuticals announced its financial results for the quarter ending December 2024, revealing a flat overall performance. The company reported a Profit After Tax of Rs 478.94 crore, reflecting a year-on-year growth of 26.92%, while facing challenges with a declining Debtors Turnover Ratio.
Glaxosmithkline Pharmaceuticals has recently reported its financial results for the quarter ending December 2024, with the announcement made on February 14, 2025. The company has experienced a flat financial performance during this period, and there has been an adjustment in its evaluation, with the score reflecting a notable decline over the last three months.On a positive note, the Profit After Tax (PAT) for the half-year stands at Rs 478.94 crore, showcasing a year-on-year growth of 26.92%. This indicates a favorable near-term trend in profitability for Glaxosmithkline Pharmaceuticals.
Conversely, the company has faced challenges, particularly with its Debtors Turnover Ratio, which has reached its lowest point at 13.27 times. This metric has shown a consistent decline over the last five half-year periods, suggesting a slowdown in the pace at which the company is settling its debts.
Overall, Glaxosmithkline Pharmaceuticals is navigating a complex financial landscape, with both positive growth in PAT and concerns regarding its debtor management.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
